Where does AbCellera Biologics Inc.'s cash flow data come from?

Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$146.41M+10.1%	-$162.86M-11.2%	-$146.4M—	——
Depreciation and amortization	$18.39M+47.7%	$12.46M-3.0%	$12.84M+43.8%	$8.93M+99.2%
Stock-based compensation	$55.79M-17.4%	$67.58M+5.3%	$64.18M+29.7%	$49.48M+61.5%
Change in accounts payable	$3.46M-67.5%	$10.64M+170%	-$15.1M-621%	-$2.09M—
Change in other assets	-$17.15M-188%	-$5.95M+67.4%	-$18.25M—	——
Other working capital changes	$3.33M—	——	-$2.24M—	——
Change in deferred revenue	——	——	-$13.98M-326%	$6.18M—
Change in income taxes payable/receivable	-$29.84M-549%	$6.65M-78.2%	$30.46M+134%	-$88.61M—
Amortization of intangible assets	——	——	——	——
Non-cash operating lease expense	$6.65M+8.1%	$6.15M-5.4%	$6.5M+23.6%	$5.26M+88.8%
Change in receivables	$55.62M-26.0%	$75.12M+63.5%	$45.93M—	——
Distributions from equity method investments	$30.11M—	$0—	$0—	——
Net cash from operating activities	-$131.3M-20.9%	-$108.56M—	——	——
Capital expenditures	$42.77M-45.4%	$78.4M+1.9%	$76.95M+8.9%	$70.66M+20.9%
Net change in loans and leases	-$33.27M—	$0—	$0—	——
Net cash from investing activities	$87.75M-27.7%	$121.41M+155%	-$221.11M+37.3%	-$352.63M-6.1%
Net cash from financing activities	——	$12.77M+23.3%	$10.36M—	——
Effect of exchange rate changes on cash	——	——	$589K+106%	-$9.96M-599%
Net increase (decrease) in cash	——	$23.01M+109%	-$254.04M—	——
Amortization of capitalized software and acquired intangible assets	$3.7M—	——	——	——
Depreciation	$18.39M+47.7%	$12.46M-3.0%	$12.84M+43.8%	$8.93M+99.2%
Distributions of earnings from equity method investees	$30.11M—	$0—	$0—	——
Gain (Loss) on Contingent Consideration and Investments	-$4.53M-107%	$64.73M+707%	$8.02M+359%	-$3.09M—
Increase Decrease In Deferred Grant Income	$3.64M+111%	-$33.97M+14.1%	-$39.52M-327%	-$9.26M+69.8%
Deferred revenue	——	——	-$13.98M-326%	$6.18M—
Increase (Decrease) in Other Operating Assets	-$17.15M-188%	-$5.95M+67.4%	-$18.25M—	——
Operating lease right-of-use asset amortization	$6.65M+8.1%	$6.15M-5.4%	$6.5M+23.6%	$5.26M+88.8%
Other Noncash Income (Expense)	$3.33M—	——	-$2.24M+33.1%	-$3.34M-142%
Payments for (Proceeds from) Loans Receivable	-$33.27M—	$0—	$0—	——
Payments To Acquire (Proceeds from) Long Term Investments And Other Assets	$17.09M—	——	$45.21M+160%	$17.37M—
Receipt of grant funding	$21.34M-40.2%	$35.71M+41.1%	$25.31M+54.0%	$16.43M—
Proceeds from long-term liabilities and other	$29.73M+120%	$13.5M+16.5%	$11.59M+321%	$2.76M-49.8%
Proceeds from long-term liabilities and other	——	——	——	——
Free cash flow	-$174.07M+6.9%	-$186.95M-54.7%	-$120.82M—	——
Free cash flow	-$174.07M+6.9%	-$186.95M-54.7%	-$120.82M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does AbCellera Biologics Inc.'s cash flow data come from?: Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.